HC Wainwright Research Analysts Decrease Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at HC Wainwright reduced their Q2 2024 earnings per share estimates for Zevra Therapeutics in a report issued on Tuesday, July 9th. HC Wainwright analyst O. Livnat now expects that the company will earn ($0.50) per share for the quarter, down from their previous estimate of ($0.44). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q3 2024 earnings at ($0.48) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.64) EPS, FY2025 earnings at $0.29 EPS and FY2028 earnings at $3.08 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. Zevra Therapeutics had a negative return on equity of 82.55% and a negative net margin of 181.76%. The company had revenue of $3.43 million for the quarter, compared to the consensus estimate of $3.52 million.

A number of other equities research analysts also recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research report on Monday, April 1st. Maxim Group raised their price target on Zevra Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $19.50.

Zevra Therapeutics Trading Up 8.7 %

Shares of ZVRA stock opened at $6.11 on Friday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.10 and a current ratio of 2.10. Zevra Therapeutics has a 52-week low of $3.89 and a 52-week high of $7.28. The company has a market capitalization of $255.72 million, a PE ratio of -4.53 and a beta of 1.97. The business’s fifty day moving average is $4.74 and its 200 day moving average is $5.41.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ZVRA. VisionPoint Advisory Group LLC bought a new position in shares of Zevra Therapeutics during the third quarter valued at about $33,000. SG Americas Securities LLC grew its stake in shares of Zevra Therapeutics by 41.7% during the fourth quarter. SG Americas Securities LLC now owns 20,999 shares of the company’s stock valued at $138,000 after buying an additional 6,175 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of Zevra Therapeutics by 555.0% during the fourth quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock valued at $43,000 after buying an additional 5,550 shares during the last quarter. Strs Ohio grew its stake in shares of Zevra Therapeutics by 151.9% during the fourth quarter. Strs Ohio now owns 19,400 shares of the company’s stock valued at $127,000 after buying an additional 11,700 shares during the last quarter. Finally, Kovack Advisors Inc. grew its stake in shares of Zevra Therapeutics by 13.9% in the fourth quarter. Kovack Advisors Inc. now owns 141,401 shares of the company’s stock worth $926,000 after purchasing an additional 17,292 shares during the last quarter. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.